Viventia Bio Inc.
Records under this name other than the patents Viventia Bio Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,697,075 | Cancer specific antibody and cell surface proteins Term ended Term ended Dec 21, 2025 · USPTO record | Term ended | Term ended Dec 21, 2025 | USPTO record |
| US 9,822,182 | Anti-EPCAM antibodies and methods of use Lapsed on the fee record Ended Nov 21, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 21, 2025 | USPTO record |
| US 8,969,540 | Tumor Specific Antibody Term ended Term ended Jun 10, 2025 · Medium confidence | Term ended | Term ended Jun 10, 2025 | Medium confidence |
| US 8,389,286 | Cancer-associated antigen Lapsed on the fee record Ended Mar 5, 2025 · USPTO record | Lapsed on the fee record | Ended Mar 5, 2025 | USPTO record |
| US 8,318,472 | Optimized nucleic acid sequences for the expression of VB4-845 Lapsed on the fee record Ended Nov 27, 2024 · USPTO record | Lapsed on the fee record | Ended Nov 27, 2024 | USPTO record |
| US 8,263,744 | Binding proteins that bind to EpCAM linked to an effector molecule Lapsed on the fee record Ended Sep 11, 2024 · USPTO record | Lapsed on the fee record | Ended Sep 11, 2024 | USPTO record |
| US 8,426,561 | Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof Lapsed on the fee record Ended Apr 23, 2021 · USPTO record | Lapsed on the fee record | Ended Apr 23, 2021 | USPTO record |
| US 8,383,117 | CD44E tumor specific antibody Formerly held Lapsed on the fee record Ended Feb 26, 2021 · USPTO record | Lapsed on the fee record | Ended Feb 26, 2021 | USPTO record |
| US 8,273,550 | Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof Lapsed on the fee record Ended Sep 25, 2020 · USPTO record | Lapsed on the fee record | Ended Sep 25, 2020 | USPTO record |
| US 6,207,153 | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers Term ended Term ended May 22, 2017 · USPTO record | Term ended | Term ended May 22, 2017 | USPTO record |